Aethlon Medical (AEMD) Emerging Growth Conference summary

Mission and technology overview

• Focused on improving outcomes for patients with life-threatening diseases by enhancing the effectiveness of existing therapies, not replacing them.

• Hemopurifier is a blood filtration device designed to remove harmful particles, such as extracellular vesicles (EVs), from the bloodstream.

• Device complements a wide range of therapies and is not limited to a single disease area.

Clinical progress and trial updates

• Ongoing Australian oncology trial targets cancer patients unresponsive to Keytruda or Opdivo, showing reductions in EVs and positive immune biomarker changes.

• Seven out of nine patients have been treated; completion and data analysis are next steps before regulatory meetings.

• Each clinical milestone reduces risk and advances toward commercialization.

Differentiation and platform potential

• Approach differs from most cancer therapies by targeting the tumor environment rather than cancer cells directly.

• Platform technology has potential applications in oncology, infectious diseases, long COVID, and other conditions involving harmful circulating particles.

• Previous use during the 2014 Ebola outbreak demonstrated the device's ability to reduce viral load in a critically ill patient.